Drugs / tgAAVCF
tgAAVCF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00073463 | Jun 2003 → Oct 2005 | cystic fibrosis | Targeted Genetics Corporation | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tgAAVCF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00073463 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Recombinant Adeno-Associated Virus Containing the CFTR Gene” NCT00073463 ↗ |
| Route | Inhaled | “Aerosolized tgAAVCF” NCT00073463 ↗ |
| Target | CFTR | “tgAAVCF, which has been genetically engineered to contain the CFTR gene” NCT00073463 ↗ |